Journal
CELL CYCLE
Volume 10, Issue 14, Pages 2323-2330Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.10.14.16399
Keywords
ATM; ATR; DNMT1; HL-60; MOLM-13; SKM-1
Categories
Funding
- Post Accueil INSERM
- INCA
- Fondation pour la Recherche Medicale (FRM)
- Ligue contre le Cancer
- Apo-Sys
- Canceropole Ile-de-France
- Institut National du Cancer (INCa)
- Fondation de France
- Association Laurette Fugain
- Cent pour Sang la Vie
- Agence National de la Recherche
- FRM
- European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train)
- Fondation de France and Cent pour Sang la Vie
Ask authors/readers for more resources
The deregulation of the DNA damage response DDR) can contribute to leukemogenesis and favor the progression from myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML). Since hypomethylating agents-notably azacitidine-constitute an efficient therapy for patients with high-risk MDS, we assessed whether such compounds can activate the DDR in malignant blasts. While azacitidine and decitabine had moderate effects on apoptosis and cell cycle progression, both agents induced profound changes in the expression and functionality of DDR-related proteins. Decitabine-and to a lesser degree azacitidine-induced the activation of checkpoint kinases Chk-1 and Chk-2, and the phosphorylation of the DDR-sensor H2AX. In addition, hypomethylating agents were found to cause the dephosphorylation of the transcriptional regulator forkhead box O3, best known as FOXO3A, whose phosphorylation has been related to poor prognosis in AML. The dephosphorylation of FOXO3A induced by azacitidine or decitabine in malignant blasts was accompanied by the translocation of FOXO3A from the cytoplasm to the nucleus. Upon stimulation with azacitidine, MDS/AML-derived, azacitidine-sensitive SKM-1S cells upregulated FOXO3A and the pro-apoptotic FOXO3A targets BIM and PUMA, and this effect was attenuated or abolished in azacitidine-resistant SMK-1R cells. Altogether, our results suggest that the re-activation of FOXO3A may contribute to the effects of hypomethylating agents in malignant blasts.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available